Subsequent to those case series, a clinical trial of ASPS patients treated with cediranib (known as a potent VEGFR inhibitor) was performed; in the phase 2 trial, 46 ASPS patients were enrolled and of them, 15 patients (35%) had a partial response [53]. This evidence concerns the gene KDR and alveolar soft part sarcoma.